GlassScriptPhysician profile
Leiv M Takle
NPI 1609807445
$11,572.28
in general payments reported to CMS, 2019-2025
33 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $520 · 2021: $964 · 2022: $2,377 · 2023: $1,819 · 2024: $3,904 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,430 · Consulting Fee: $2,750 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,430.39 |
| Consulting Fee | $2,750.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $2,791.05 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Alcon Vision LLC | $2,640.53 | 2019-2025 | Clareon, Lensx, Centurion |
| Notal Vision, INC. | $1,213.43 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $711.46 | 2021-2025 | Quatera 700, Lumera 700, Clarus |
| Abbvie INC. | $678.28 | 2022-2025 | Durysta |
| Bausch & Lomb Americas INC. | $645.49 | 2022-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Glaukos Corporation | $477.83 | 2021-2025 | Idose, Idosetr, Ce-Marked Kxla System |
| Allergan, INC. | $443.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $366.80 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $283.30 | 2020-2025 | Cequa |
| Sight Sciences, INC. | $265.26 | 2021-2023 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $197.84 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $188.24 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Kala Pharmaceuticals, INC. | $70.91 | 2021 | |
| Amgen INC. | $68.92 | 2025 | Tepezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $67.52 | 2022-2024 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $53.85 | 2022-2025 | Oxervate |
| Harrow Eye, LLC | $52.84 | 2023-2025 | Vevye, Iheezo |
| Horizon Therapeutics Plc | $49.91 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $45.37 | 2022-2023 | Eylea |
| Tarsus Pharmaceuticals, INC. | $43.47 | 2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $28.48 | 2020 | |
| Sandoz INC. | $26.11 | 2024 | Cimerli |
| Ivantis, INC | $24.55 | 2021 | |
| Thea Pharma INC. | $20.02 | 2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $16.93 | 2021 | |
| Biotissue Holdings INC. | $16.36 | 2025 | |
| Glaxosmithkline, LLC. | $16.06 | 2025 | Blenrep |
| New World Medical,INC. | $15.50 | 2019 | |
| Iridex Corporation | $15.49 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.47 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $12.06 | 2019 | |
| Omeros Corporation | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leiv Takle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.